Login to Your Account



Tivantinib Misses Again

Midstage Colorectal Cancer Data Dent ArQule's Shares

By Jennifer Boggs
Managing Editor

Monday, January 14, 2013
Three months after its shares were clobbered on disappointing survival data in non-small-cell lung cancer (NSCLC), ArQule Inc.'s stock sank again, after tivantinib, its MET inhibitor, missed primary and secondary endpoints in a Phase II trial in second-line colorectal cancer (CRC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription